AR123537A1 - Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca - Google Patents
Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíacaInfo
- Publication number
- AR123537A1 AR123537A1 ARP210102585A ARP210102585A AR123537A1 AR 123537 A1 AR123537 A1 AR 123537A1 AR P210102585 A ARP210102585 A AR P210102585A AR P210102585 A ARP210102585 A AR P210102585A AR 123537 A1 AR123537 A1 AR 123537A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- binding
- binding molecule
- hla
- cell
- Prior art date
Links
- 208000015943 Coeliac disease Diseases 0.000 title 1
- 230000027455 binding Effects 0.000 abstract 18
- 239000000427 antigen Substances 0.000 abstract 16
- 102000036639 antigens Human genes 0.000 abstract 16
- 108091007433 antigens Proteins 0.000 abstract 16
- 108010068370 Glutens Proteins 0.000 abstract 5
- 235000021312 gluten Nutrition 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Reivindicación 1: Una molécula de unión a antígeno multiespecífica que comprende: (I) una primera porción de unión a antígeno que tiene actividad de unión a HLA-DQ2.5 en la forma de un complejo con un péptido de gluten; y (II) una segunda porción de unión a antígeno que tiene actividad de unión a HLA-DQ2.5 en la forma de un complejo con un péptido de gluten; caracterizada por que la molécula de unión a antígeno se une a dos o más complejos de HLA-DQ2.5 y péptidos de gluten, donde al menos uno de los péptidos de gluten en los complejos unidos por la primera porción de unión a antígeno es diferente de al menos uno de los péptidos de gluten en los complejos unidos por la segunda porción de unión a antígeno; y donde la molécula de unión a antígeno no tiene sustancialmente actividad de unión a uno o ambos de una célula B de PBMC positiva para HLA-DQ2.5 y una célula Ba/F3 que expresa HLA-DQ2.5, donde la molécula de unión a antígeno es humanizada, y donde se alteran uno o más aminoácidos en una cadena pesada y/o en una cadena ligera de la primera porción de unión a antígeno y/o la segunda porción de unión a antígeno en la molécula de unión a antígeno multiespecífica. Reivindicación 37: Un ácido nucleico que codifica la molécula de unión a antígeno multiespecífica de una cualquiera de reivindicaciones 1 a 35. Reivindicación 38: Un vector que comprende el ácido nucleico de la reivindicación 37. Reivindicación 39: Una célula que comprende el ácido nucleico aislado de la reivindicación 37 o el vector de la reivindicación 38. Reivindicación 40: Un método para producir una molécula de unión a antígeno multiespecífica que comprende cultivar la célula de la reivindicación 39 de manera que se produzca la molécula de unión a antígeno multiespecífica. Reivindicación 42: Una composición farmacéutica que comprende la molécula de unión a antígeno multiespecífica de una cualquiera de reivindicaciones 1 a 35 o la combinación de la reivindicación 36 y un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020157873 | 2020-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123537A1 true AR123537A1 (es) | 2022-12-14 |
Family
ID=80739984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102585A AR123537A1 (es) | 2020-09-18 | 2021-09-17 | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11739153B2 (es) |
| EP (1) | EP4214236A1 (es) |
| JP (2) | JP7147030B2 (es) |
| KR (2) | KR20230116942A (es) |
| CN (3) | CN117801114A (es) |
| AR (1) | AR123537A1 (es) |
| AU (1) | AU2021343008A1 (es) |
| CA (1) | CA3192661A1 (es) |
| CL (1) | CL2023000765A1 (es) |
| CO (1) | CO2023003681A2 (es) |
| CR (1) | CR20230166A (es) |
| IL (1) | IL301326A (es) |
| MX (1) | MX2023002191A (es) |
| PE (1) | PE20231208A1 (es) |
| TW (2) | TWI820484B (es) |
| WO (1) | WO2022059766A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7147030B2 (ja) | 2020-09-18 | 2022-10-04 | 中外製薬株式会社 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
| WO2023058705A1 (ja) * | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | 抗ｈｌａ－ｄｑ２．５抗体の製剤 |
| JP7220335B1 (ja) * | 2021-10-08 | 2023-02-09 | 中外製薬株式会社 | 抗ｈｌａ－ｄｑ２．５抗体の製剤 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| MXPA03009313A (es) | 2001-04-12 | 2004-11-12 | Academish Ziekenhuis Leiden | Metodos y medios para uso de receptores de celulas t restringidos por hla-dq y peptidos derivados de prolamina unidos a hla-dq. |
| WO2009099641A2 (en) | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
| AU2013204429B9 (en) | 2008-11-30 | 2017-01-05 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
| WO2010141658A1 (en) | 2009-06-04 | 2010-12-09 | The Regent Of The University Of Colorado | Therapeutic compositions and methods for the prevention of autoimmune diseases |
| RU2013106217A (ru) | 2010-08-05 | 2014-09-10 | Ф. Хоффманн-Ля Рош Аг | Гибридный белок из антитела против мнс и противовирусного цитокина |
| KR102168733B1 (ko) * | 2011-10-31 | 2020-10-23 | 추가이 세이야쿠 가부시키가이샤 | 중쇄와 경쇄의 회합이 제어된 항원 결합 분자 |
| WO2016202805A2 (en) | 2015-06-15 | 2016-12-22 | Consejo Superior De Investigaciones Científicas (Csic) | Targeting of prolamin by rnai in bread wheat |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| US20200040085A1 (en) * | 2017-02-27 | 2020-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease |
| CN117777294A (zh) * | 2017-10-03 | 2024-03-29 | 中外制药株式会社 | 抗hla-dq2.5抗体 |
| GB201802338D0 (en) | 2018-02-13 | 2018-03-28 | Univ Oslo | Antigen binding proteins |
| EP3947466A4 (en) | 2019-04-01 | 2022-12-28 | Chugai Seiyaku Kabushiki Kaisha | ANTI-HLA-DQ2.5 ANTIBODIES |
| JP7147030B2 (ja) | 2020-09-18 | 2022-10-04 | 中外製薬株式会社 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
-
2021
- 2021-09-17 JP JP2021151709A patent/JP7147030B2/ja active Active
- 2021-09-17 CN CN202311813323.8A patent/CN117801114A/zh active Pending
- 2021-09-17 EP EP21869449.5A patent/EP4214236A1/en active Pending
- 2021-09-17 CA CA3192661A patent/CA3192661A1/en active Pending
- 2021-09-17 IL IL301326A patent/IL301326A/en unknown
- 2021-09-17 CR CR20230166A patent/CR20230166A/es unknown
- 2021-09-17 KR KR1020237024631A patent/KR20230116942A/ko active Search and Examination
- 2021-09-17 AU AU2021343008A patent/AU2021343008A1/en active Pending
- 2021-09-17 CN CN202311818773.6A patent/CN117801115A/zh active Pending
- 2021-09-17 US US17/477,651 patent/US11739153B2/en active Active
- 2021-09-17 AR ARP210102585A patent/AR123537A1/es unknown
- 2021-09-17 CN CN202180061976.8A patent/CN116096757B/zh active Active
- 2021-09-17 MX MX2023002191A patent/MX2023002191A/es unknown
- 2021-09-17 PE PE2023001173A patent/PE20231208A1/es unknown
- 2021-09-17 TW TW110134821A patent/TWI820484B/zh active
- 2021-09-17 KR KR1020217042982A patent/KR102559128B1/ko active IP Right Grant
- 2021-09-17 TW TW112137009A patent/TW202402804A/zh unknown
- 2021-09-17 WO PCT/JP2021/034240 patent/WO2022059766A1/en active Application Filing
-
2022
- 2022-09-02 JP JP2022139889A patent/JP2022172276A/ja active Pending
-
2023
- 2023-03-16 CL CL2023000765A patent/CL2023000765A1/es unknown
- 2023-03-23 CO CONC2023/0003681A patent/CO2023003681A2/es unknown
- 2023-07-05 US US18/346,975 patent/US20230357408A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4214236A1 (en) | 2023-07-26 |
| TW202402804A (zh) | 2024-01-16 |
| MX2023002191A (es) | 2023-03-03 |
| JP2022172276A (ja) | 2022-11-15 |
| TWI820484B (zh) | 2023-11-01 |
| CO2023003681A2 (es) | 2023-04-05 |
| IL301326A (en) | 2023-05-01 |
| WO2022059766A1 (en) | 2022-03-24 |
| AU2021343008A1 (en) | 2023-06-01 |
| PE20231208A1 (es) | 2023-08-17 |
| JP2022051553A (ja) | 2022-03-31 |
| KR102559128B1 (ko) | 2023-07-24 |
| CA3192661A1 (en) | 2022-03-24 |
| KR20230116942A (ko) | 2023-08-04 |
| AU2021343008A9 (en) | 2024-10-10 |
| US20230357408A1 (en) | 2023-11-09 |
| CL2023000765A1 (es) | 2023-11-03 |
| US11739153B2 (en) | 2023-08-29 |
| CN117801114A (zh) | 2024-04-02 |
| CN117801115A (zh) | 2024-04-02 |
| KR20220153469A (ko) | 2022-11-18 |
| CN116096757A (zh) | 2023-05-09 |
| TW202229345A (zh) | 2022-08-01 |
| CN116096757B (zh) | 2024-01-12 |
| US20220089743A1 (en) | 2022-03-24 |
| JP7147030B2 (ja) | 2022-10-04 |
| CR20230166A (es) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| AR110101A1 (es) | Miembros de unión (2) | |
| AR127516A2 (es) | VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN | |
| AR111203A1 (es) | Inmunoconjugados | |
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| AR112257A1 (es) | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos | |
| PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| MX2022016192A (es) | Anticuerpos anti-nectina-4 condicionalmente activos. | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| PE20220489A1 (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso | |
| PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| RU2021128024A (ru) | Способы культивирования клеток | |
| BR112022011357A2 (pt) | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo | |
| AR128688A1 (es) | Anticuerpos anti-cd39 y uso de los mismos | |
| PE20211497A1 (es) | Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso |